Fig. 1: Design of the OSCILLATE trial. | Nature Communications

Fig. 1: Design of the OSCILLATE trial.

From: A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Fig. 1

a Clinical trial consort diagram with final number of participants recruited and analyzed. Plasma samples were collected serially as shown. Baseline and progression plasma samples were characterized using the assays listed for the detection of potential genomic resistance markers. b Clinical trial design of the OSCILLATE study and overview of plasma sample collection for translational research. Participants with EGFR T790M positive advanced NSCLC were treated with an alternating regimen of osimertinib and gefitinib until progression, unacceptable toxicity, or death. NSCLC non-small cell lung cancer. ctDNA circulating tumor DNA.

Back to article page